Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

Despite Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Zoetis (NYSE:ZTS) added ~7% in the premarket on Tuesday after the animal health company exceeded Street forecasts with its Q2 ...

Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% ...

Zoetis Inc. Q2 2025 earnings highlight 8% organic revenue growth, raised guidance, and strong performance from Simparica and Key Dermatology franchises.

Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness.

Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET. Company Participants. Kristin C. Peck - CEO & Director Steven Frank - Vice President of Investor ...

The company raised its full-year 2025 guidance, now expecting revenue between $9.45 billion and $9.6 billion, representing ...

We came across a bullish thesis on Zoetis Inc. on Bob’s Payment Stock Substack by Bob Hammel. In this article, we will ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and vaccines for pets, sending the animal healthcare company's shares surging ...